Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6751695 | 0.80 | CA12 (0.35) | ALDH1A1SMN1; SMN2TSHRL3MBTL1CA12 | |
| SCHEMBL6752707 | 0.76 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2TSHRCA12CA7 | |
| SCHEMBL13588748 | 0.73 | MEN1 (0.47) | ALDH1A1SMN1; SMN2TSHRL3MBTL1KDM4E | |
| SCHEMBL14997963 | 0.72 | ALDH1A1 (0.43) | ALDH1A1TSHRL3MBTL1CA12CA7 | |
| SCHEMBL27599227 | 0.71 | APP (0.34) | ALDH1A1SMN1; SMN2TSHRL3MBTL1CA12 | |
| SCHEMBL4912207 | 0.69 | LMNA (0.39) | ALDH1A1SMN1; SMN2TSHRKDM4E | |
| SCHEMBL12890114 | 0.67 | ALDH1A1 (0.34) | ALDH1A1SMN1; SMN2TSHRKDM4E | |
| SCHEMBL4823292 | 0.66 | TSHR (0.36) | ALDH1A1SMN1; SMN2TSHRL3MBTL1KDM4E | |
| SCHEMBL6753810 | 0.66 | PRKDC (0.49) | ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL4911938 | 0.66 | LMNA (0.49) | ALDH1A1SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142946-A1 | Modified nucleosides and nucleotides and use thereof | CHATTOPADHYAYA JYOTI (SE) | 2004-07-22 | — | — | US | claimed |
| EP-1332150-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES AND USE THEREOF | Chattopadhyaya, Jyoti (SE) | 2003-08-06 | — | — | EP | claimed |
| WO-2002038578-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES AND USE THEREOF | CHATTOPADHYAYA JYOTI (SE) | 2002-05-16 | — | — | WO | claimed |
| US-5721350-A | Deuterated nucleosides | CHATTOPADHYAYA JYOTI (SE) | 1998-02-24 | — | — | US | claimed |
| WO-1993025566-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA JYOTI (SE) | 1993-12-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142946-A1 | Modified nucleosides and nucleotides and use thereof | RNASEH1, RNASEL, NSUN2 | ALDH1A1 4684/4885SMN1; SMN2 1974/4885TSHR 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.